Glaxosmithkline Pharmaceuticals consolidated net profit rises 37.87% in the June 2024 quarter

Glaxosmithkline Pharmaceuticals’ standalone net profit jumped 39.11% to Rs 181.65 crore in Q1 FY25 as compared to Rs 130.58 crore posted in Q1 FY24.

GSK Pharma Q1 PAT climbs 39% YoY to Rs 182 crore

GSK Pharma Q1 results: GSK Pharma’s stocks were up by 2.49 per cent, ending the day’s trade at Rs 2,824.45 apiece on the Bombay Stock Exchange (BSE)

GSK Pharma Q1 results: Net profit rises 37%, revenue up 6.9%

The company had posted a consolidated net profit of Rs 132.25 crore in the same quarter last fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing

GSK Pharmaceuticals Q1 results: Net profit jumps 38% to Rs 182.33 crore

The Indian market recouped losses to close flat with a negative bias on the Budget Day. The S&P BSE Sensex fell 0.09% while the Nifty50 closed below 24,500 levels.“Nifty recovered from its intraday low of 24,074.20 but failed to close in the green. The immediate support lies at 24,400, with strong resistance at 24,570,” said Dhupesh Dhameja, Technical Analyst, SAMCO Securities.“To regain bullish momentum, the Nifty must sustain above 24,400. Failure to do so could trigger profit booking, potentially pushing the index down to 24,200,” he added. Market Outlook

Technical Breakout Stocks: Budget Day volatility! Suzlon, GlaxoSmithkline Pharma and Federal Bank hit fresh 52-week highs - Market Outlook

MTNL, Sonam Clock, Pondy Oxides, GSK Pharma and Power & Instrument, hit their fresh 52-week highs at 10:29AM.

Stock market update: Stocks that hit 52-week highs on NSE

Glaxosmithkline Pharmaceuticals announces change in senior management

GSK Pharma’s recent good showing is on expectations that launches in the specialty segment, increasing investments in promotions and branding

New product launches may continue to fuel GSK Pharma’s robust growth

Total income increased to Rs 833 crore for the third quarter of the current fiscal as compared with Rs 826 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement.

GlaxoSmithKline Pharma Q3 net profit dips 72% to Rs 46 cr

Here are the stocks to watch before going into trade today.

Stocks To Watch: Reliance Industries, Jio, LIC, GlaxoSmithKline Pharma, PNB, Sula Vineyards, Nykaa

GlaxoSmithKline Consolidated June 2023 Net Sales at Rs 761.66 crore, up 2.22% Y-o-Y

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.